Four Color, Enumeration Probe
Several screening programs for cervical cancer have been implemented in the clinical community, and are comprised of tests based on the appearance of abnormal cells in cytological specimens, and more recently, based on HPV type. There remains, however, a great need for additional biomarkers that will increase the sensitivity with which precancerous and cancerous lesions are detected. Furthermore, there is a lack of testing available for the identification of atypical or moderately abnormal squamous cell lesions that will progress to higher grades.
Cancer Genetics, Inc. has developed the FISH-based HPV-Associated Cancer Test, FHACTâ„¢. This test is intended to aid in identifying specimens with clonal chromosomal aberrations commonly detected in cervical cancer.
The FISH (Fluorescence in situ hybridization) analysis is performed on nuclei of cells derived from a liquid pap specimen (PreservCytÂ® or SurePathÂ®), using the FHACTâ„¢ combination probe (manufactured by CGI Italia): 3q26 (TERC) (red), 5p15 (D5S2095) (green), 20q13 (D20S911) (gold) and CEP7 (aqua).
The FISH Probe has been optimized to identify copy number gains of 3q26, 5p15, chromosome 7 and 20q13. In normal diploid interphase and metaphase cells, FHACTâ„¢ generates two red, two green, two blue and two gold signals corresponding to the normal chromosomes 3, 5, 7 and 20 respectively. In cells with gain or amplification of 3q26, 5p15, 20q13 and/or chromosome 7, the number of red, green, gold and/or blue signals will be greater than two each.
FHACTâ„¢ results should be used in conjunction with cytological findings.
Please contact us for more information about our FHACTâ„¢ Probe.
FHACTâ„¢ is a trademark of Cancer Genetics, Inc.